Bulletin
Investor Alert

Harrow Health Inc.

NAS: HROW

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Oct 18, 2021, 4:00 p.m.

/zigman2/quotes/206805265/composite

$

10.29

Change

0.00 0.00%

Volume

Volume 538

Quotes are delayed by 20 min

/zigman2/quotes/206805265/composite

Today's close

$ 9.89

$ 10.29

Change

+0.40 +4.04%

Day low

Day high

$8.99

$10.48

Open

52 week low

52 week high

$4.65

$11.24

Open

Company Description

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the Pharmaceutical Compounding and Pharmaceutical Drug Development segments. The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was fo...

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the Pharmaceutical Compounding and Pharmaceutical Drug Development segments. The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Valuation

P/E Ratio (with extraordinary items)

37.49

Price to Sales Ratio

3.63

Price to Book Ratio

6.50

Enterprise Value to EBITDA

56.79

Enterprise Value to Sales

3.44

Total Debt to Enterprise Value

0.14

Efficiency

Revenue/Employee

390,968.00

Income Per Employee

-26,856.00

Receivables Turnover

18.12

Total Asset Turnover

0.84

Liquidity

Current Ratio

3.72

Quick Ratio

3.35

Cash Ratio

3.03

Profitability

Gross Margin

70.41

Operating Margin

0.18

Pretax Margin

-8.34

Net Margin

-6.87

Return on Assets

-5.76

Return on Equity

-12.23

Return on Total Capital

0.18

Return on Invested Capital

-7.26

Capital Structure

Total Debt to Total Equity

86.57

Total Debt to Total Capital

46.40

Total Debt to Total Assets

40.95

Long-Term Debt to Equity

70.07

Long-Term Debt to Total Capital

37.56

Officers and Executives

Name Age Officer Since Title
Mr. Mark L. Baum 47 2006 Chief Executive Office & Director
Mr. Andrew R. Boll 37 2011 Chief Financial Officer & Secretary
Dr. Larry M. Dillaha 55 - Chief Medical Officer
Mr. Andrew Livingston - - Chief Innovation Officer
Mr. John P. Saharek 60 2012 Vice President-Commercialization

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
09/24/2021 Richard L. Lindstrom
Director
3,900   Disposition at $10.04 per share. 39,156
09/16/2021 Richard L. Lindstrom
Director
5,840   Disposition at $9.02 per share. 52,676
09/15/2021 Richard L. Lindstrom
Director
14,160   Disposition at $9.09 per share. 128,714
08/19/2021 Opaleye Management, Inc.
2,500   Acquisition at $8.44 per share. 21,100
08/19/2021 Opaleye Management, Inc.
50,000   Acquisition at $8.44 per share. 422,000
08/18/2021 Opaleye Management, Inc.
1,500   Acquisition at $8.64 per share. 12,960
08/18/2021 Opaleye Management, Inc.
45,000   Acquisition at $8.64 per share. 388,800
08/17/2021 Opaleye Management, Inc.
1,000   Acquisition at $8.57 per share. 8,570
08/17/2021 Opaleye Management, Inc.
25,000   Acquisition at $8.57 per share. 214,250
07/21/2021 Opaleye Management, Inc.
4,706   Acquisition at $7.6 per share. 35,765
07/21/2021 Opaleye Management, Inc.
4,500   Acquisition at $7.6 per share. 34,200
07/20/2021 Opaleye Management, Inc.
125   Acquisition at $7.2 per share. 900
07/20/2021 Opaleye Management, Inc.
4,800   Acquisition at $7.2 per share. 34,560
07/19/2021 Opaleye Management, Inc.
169   Acquisition at $6.97 per share. 1,177
07/19/2021 Opaleye Management, Inc.
5,700   Acquisition at $6.97 per share. 39,729
06/18/2021 Opaleye Management, Inc.
3,522   Acquisition at $8.35 per share. 29,408
06/18/2021 Opaleye Management, Inc.
59,800   Acquisition at $8.35 per share. 499,330
/news/latest/company/us/hrow

MarketWatch News on HROW

  1. Imprimis Pharma initiated as buy at B Riley FBR

    3:11 p.m. Dec. 13, 2018

    - Ciara Linnane

  2. Express Scripts opts for $1 alternative to Turing’s $750 Daraprim

    6:56 a.m. Dec. 1, 2015

    - Jonathan D. Rockoff

  3. Duckburg Economics: Pricing and Scarcity in Drugs

    12:44 a.m. Oct. 31, 2015

    - Barron's Online

/news/nonmarketwatch/company/us/hrow

Other News on HROW

  1. Harrow Health: Good Opportunity For Growth Investors

    12:16 p.m. Aug. 22, 2021

    - Seeking Alpha

  2. SRK Capital's 2021 H1 Partnership Letter

    11:00 a.m. Aug. 13, 2021

    - Seeking Alpha

  3. What's in Store for Harrow Health (HROW) in Q2 Earnings?

    10:57 a.m. Aug. 5, 2021

    - Zacks.com

  4. Yes, You Can Retire On Dividends

    8:35 a.m. June 23, 2021

    - Seeking Alpha

  5. Harrow Health prices 8.625% senior notes due 2026

    2:10 a.m. June 15, 2021

    - Seeking Alpha

  6. Harrow Health to raise $17.5M via senior notes offering

    8:02 a.m. June 14, 2021

    - Seeking Alpha

  7. Loading more headlines...

At a Glance

Harrow Health, Inc.

102 Woodmont Boulevard

Suite 610

Nashville, Tennessee 37205

Phone

1 6157334730

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$48.87M

Net Income

$-3.36M

Employees

125.00

/news/pressrelease/company/us/hrow

Press Releases on HROW

  1. Harrow Health Announces Second Quarter 2021 Financial Results

    4:01 p.m. Aug. 10, 2021

    - BusinessWire - BZX

  2. Harrow Health Launches New Corporate and Investor Website

    9:19 a.m. June 1, 2021

    - GlobeNewswire

  3. Harrow Health, Inc. to Host Earnings Call

    2:45 p.m. May 11, 2021

    - ACCESSWIRE

  4. Loading more headlines...
Trending Tickers
  • /zigman2/quotes/200467500/composite NVDA+6.01%
  • /zigman2/quotes/200164174/composite SNOA+85.40%
  • /zigman2/quotes/202092269/composite ENSC+35.46%
  • /zigman2/quotes/226465160/composite ALF-14.72%
  • /zigman2/quotes/207732364/composite MSFT+1.66%
X
Powered by StockTwits
Link to MarketWatch's Slice.